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Abstract 
Helminth parasites that inhabit mammalian body surfaces have a highly evolved relationship with the 
immune system. Many of these resident helminths carry out functions to ensure their survival in the hosts. 
To attain this objective helminth parasites adopt immunoregulatory mechanisms to counter host’s hostile 
immune response. Indeed, immunomodulatory molecules have been discovered in the worm’s extracts and 
in their excretion/secretion. In this review, we discuss the state of our understanding of the interplay 
between helminths and immune pathways. We also highlight the key challenges that must be confronted in 
identification of the helminth-derived molecules involved in immune modulation.  We consider whether 
helminth-derived signaling hold promise for the design of novel therapeutic approaches for the treatment of 
inflammatory disorders (inflammatory bowel disease, allergies, and autoimmune diseases). 
  
 
1. INTRODUCTION 
Parasites and bacteria produce a wide range of molecules 
that can modulate eukaryotic immune responses. These 
include the bacterial enterotoxins, parasite-derived 
excretory-secretory products. These molecules can 
subvert protective mechanisms in order to facilitate 
pathogen colonization and persistence. In many instances 
they are able to inhibit inflammatory responses. In fact, 
there are examples of immune modulators that can exert 
either stimulatory or suppressive effects depending on 
the molecular nature, mode of delivery, timing and dose 
of exposure to the agents as well as characterization of 
the modes of action so that synthetic analogues that 
mimic the effects can be generated. There is presently 
great interest in the therapeutic exploitation of these 
factors, for example as a means to stimulate enhanced 
immune responses to a new generation of subunit 
vaccines or to inhibit deleterious immune mediated 
diseases [1, 2]. 
Exposure to commensal and pathogenic microorganisms 
strongly influences our immune system. Exposure to 
parasites and bacteria was frequent before humans 
constructed their current highly hygienic environment. 
Today, in highly industrialized countries, the contact 
between humans and the microorganism is dramatically 
diminishing. Congruent with the decline in helminthic 
and bacterial infections is an increase in the prevalence 
of autoimmune and inflammatory diseases. Incidence of 
some of these autoimmune and inflammatory diseases is 
now on the rise in the developing countries that are 
making rapid economic growth as people are adapting to 
more hygienic life-style due to affluence. It is possible 
that exclusion of many of the parasites and bacteria from 
the environment has permitted the emergence of 
immune-mediated diseases [3]. It is believed that 
parasites and humans have been co-evolved in the 
evolutionary history and the maintenance of an 
immunoregulatory environment may be promoted by 
parasites to ensure their survival in the hosts. A 
breakdown of this regulation that involves multiple 
levels of host regulatory cells and cytokines, is likely to 
4 
 
result into pathological disease.  
In this review we will highlight the process in which 
helminths modulate both the innate and the adaptive 
arms of the immune system. It is our view that 
identification of the microbes-derived molecules 
involved in immune modulation will pave the way to 
novel therapeutic approaches for the treatment of 
inflammatory diseases. Here, we provide an overview of 
the findings from animal models and clinical studies, and 
additionally explores the potential for translation of these 
findings to the clinic. 
2. BACKGROUND 
Intestinal helminth infections are of particular interest 
because they have strong immune regulatory effects on 
their host [4,5]. The most common helminth infections 
humans are caused by geohelminths (also known as 
intestinal and soil-transmitted helminths). Geohelminth 
parasites include Ascaris lumbricoides, Trichuris 
trichiura and hookworm (Ancylostoma duodenale and 
Necator americanus). Other important helminthic 
infections in humans include schistosomiasis, fascioliasis 
and filariasis, which are tissue-dwelling parasites. 
Currently, there is much interest in whether helminth-
associated immune regulation may ameliorate allergy 
and autoimmune diseases, with investigations in both 
laboratory models and human trials.  Analyses have 
consistently revealed bioactive molecules in extracts of 
helminths or in their excretory/secretory products that 
modulate the immune response of the host. Here, we 
illustrate the range of immunomodulatory molecules in 
selected parasitic trematodes, cestodes and nematodes, 
their impact on the immune cells in the host and how the 
host may recognize these molecules. Several years ago, 
we demonstrated that treatment with the extracts of 
Dipetalonema vitae male worms (a filarial nematode 
parasite) resulted into immunosuppression thereby 
enhancing the parasitemia in infected animals [6]. 
Recently, a tegumental coat antigen was isolated from 
the cestode parasite Fasciola hepatica (FhTeg) that had 
shown suppressive effect in vivo by directly targeting 
dendritic cells, impairing their ability to drive Th1 
responses. In addition, FhTeg inhibits the ability of mast 
cells to drive the Th1 immune response by suppressing 
cytokine secretion (TNF-α, IL-6, IFN-γ, and IL-10) and 
ICAM1 expression in mast cells stimulated with LPS or 
heat-inactivated Bordetella pertussis Ag [7].  
Symbiotic bacteria may be present in some nematode 
parasites.  Lipopolysaccharide-like molecules have been 
detected in sterile products of filarial nematode 
Onchocerca volvulus stages, which could originate from 
Wolbachia bacteria related to Gram-negative 
Rickettsiales. Wolbachia bacteria are known to be 
abundant in the hypodermis and the female reproductive 
organs of O. volvulus. It has been demonstrated that 
monocyte/macrophage would be a major target cell for 
immunomodulatory parasite-derived and intraparasitic, 
bacteria-derived molecules, thereby contributing to the 
host's cellular hyporesponsiveness [8]. 
Treating animals with helminths (eggs, larvae, extracts) 
causes dampening, and in some cases prevention of 
allergic and autoimmune diseases. Clinical studies 
showed that administration of eggs of Trichuris suis (a 
parasitic nematode of swine) reduces the disease severity 
to patients with inflammatory bowel disease [9]. Trials 
using colonization of helminths like Necator americanus 
(hookworm) or T. suis (porcine whipworm) show that 
they are safe and may be effective therapies for the 
control of the aberrant intestinal inflammation seen in 
Crohn's disease and ulcerative colitis [10]. Treatment 
with Schistosoma mansoni and Ancylostoma caninum 
soluble proteins significantly suppressed the 
inflammation and ameliorated trinitrobenzene sulphate 
(TNSB)-induced colitis [11]. Similar inhibitory effect on 
intestinal inflammation was observed when TNSB-
induced mice received larvae of Heligmosomoides 
polygyrus, a duodenal nematode parasite [12].  
Of note, T. suis when used in a randomized, double-
blind, placebo-controlled clinical trial in Denmark 
against allergic rhinitis, no therapeutic effect was seen 
[13]. This raises the question whether the effectiveness 
of helminth therapy, especially with live intestinal 
nematodes will be disease specific, and may not be 
efficient enough against all inflammatory diseases. 
Further, such variation may be related to host’s genetic 
or to environmental factors including the composition of 
bacterial population that colonizes the host’s gut.  
Multiple sclerosis (MS) is an inflammatory autoimmune 
demyelinating disease affecting the Central Nervous 
System (CNS), in which Th1 and Th17 cells appear to 
recognize and react against certain myelin sheath 
components [14,15]. Mucosal tolerance has been 
considered a potentially important pathway for the 
treatment of autoimmune disease, including MS and 
experimental conditions such as experimental 
autoimmune encephalomyelitis (EAE). It has been 
demonstrated that treatment with soluble products from 
the nematodes T. suis and Trichinella spiralis induces 
significant suppression of symptoms in EAE, a validated 
animal model for multiple sclerosis [16]. This 
amelioration in EAE pathogenesis is associated with the 
inhibition of TNF-α and IL-12 secretion by TLR-
activated human DCs. Furthermore, helminth-primed 
human DCs differentially suppress the development of 
Th1 and/or Th17 cells [17].  
The incidence of type 1 diabetes (TID) is increasing 
dramatically in the developed world. While there may be 
several reasons for this, improved hygienic conditions 
and public health measures have impacted our 
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interactions with certain infectious microorganisms, 
especially with helminths. Therapeutic potential of both 
live infections as well as helminth-derived products has 
been explored in the animal models of TID [18]. It was 
shown that infection with Schistosoma mansoni could 
prevent diabetes onset in NOD mice [19]. Other studies 
confirmed the potent effect of other helminth infections 
on T1D in NOD mice including Trichinella spiralis, 
Heligmosomoides polygyrus [20,21]. Protection was 
associated with an augmented Th2 response, increased 
generation of regulatory T (Treg) cells, production of IL-
10 by T and B cells and reduction in infiltrating CD8+T 
cells in the pancreas; all of which would have the 
potential to inhibit diabetes onset. Interestingly, H. 
polygyrus infection induces  non-regulatory T cells that 
produce IL-10 independently of STAT6 signaling. This 
signifies deficiency of Th2 response, and in this Th2-
deficient environment IL-10 is essential for T1D 
inhibition [21].  The use of defined parasite products to 
influence diabetes onset will provide an additional way 
of addressing mechanisms of diabetes prevention. 
A number of studies have now investigated the 
immunomodulatory mechanisms of helminth-derived 
soluble molecules in controlling allergy. [3,22]. As 
earlier as 1983, we tested the hypothesis whether Filarial 
nematode D. Viteae could produce substances that might 
down-regulate hosts’ allergic responses [23]. In this 
report, we described that a dialyzable fraction of D. vitae 
male worms’ released product inhibited passive 
cutaneous anaphylaxis (PCA, anti-ovalbumin and 
ovalbumin). In subsequent studies other researchers 
described the immunomodulatory activity of ES-62, one 
of the excretory/secretory products of the filarial worm, 
Acanthocheilonema viteae (some scientists prefer to term 
Dipetalonema viteae as Acanthocheilonema viteae). 
Molecular characterization has shown that ES-62 is a 62-
kDa phosphorylcholine (PC)–containing glycoprotein. 
ES-62–treated mice were protected in a cutaneous model 
of immediate-type hypersensitivity induced by oxazolone 
[24]. This ES-62 product has been shown to interact with 
a variety of cells of the immune system including B and 
T lymphocytes, dendritic cells, macrophages and mast 
cells. It appears that that ES-62 acts on TH17 responses 
rather than TH1 responses [25]. It has been shown that 
mice infected with nematode parasite, H. polygyrus are 
protected from allergic airway inflammation. Further, 
when the excretory-secretory material from this parasite 
was added to sensitizing doses of ovalbumin, the 
subsequent allergic airway response was suppressed, and 
this condition was associated with a lower ratio of 
effector [CD4 (+) CD25 (+) Foxp3 (-)] to regulatory 
[CD4 (+) Foxp3 (+)] T (Treg) cells, and reduced Th1, 
Th2 and Th17 cytokine production [26]. Of note, allergic 
asthma is less prevalent in countries with parasitic 
helminth infections, it appears that helminth-derived 
molecules can divert the immune system towards an anti-
inflammatory phenotype and may have therapeutic 
potential in inflammatory diseases. 
3. MECHANISMS OF ACTION 
Evidence from human studies and mouse models shows 
that infection with parasitic helminths has a suppressive 
effect on the pathogenesis of some inflammatory 
diseases [1, 5]. The overall paradigm in the way the 
helminth-derived products mediate immunomodulation 
appears to demonstrate their ability to impact the various 
immune activation pathways leading to a reduction in 
inflammation. Some helminthes and their products 
inhibit inflammatory responses through effects on both 
the innate and adaptive immune response (Fig.1). 
Helminth suppression of immunopathology generally 
involves CD4+ regulatory T cells (Tregs, either Foxp3+ 
or Foxp3−), IL-4-responsive cells, and TGF-β, IL-10 and 
Th2 cytokines. The potential regulatory role of CD8+ 
Tregs, regulatory B cells has not yet been clearly 
defined. 
The favored mechanism is that microbial and parasite-
derived products interact directly with pathogen 
recognition receptors to subvert proinflammatory 
signaling via T regulatory cells (Tregs), thereby inducing 
anti-inflammatory effects and control of autoimmune 
disease. An important immunoregulatory cytokine that 
participate in inducing tolerance is IL-10. This cytokine 
is produced by Foxp3 positive Treg cells (e.g. Tr1) [27, 
28]. Although this may suggest that Tr1 cells are 
developmentally related to Treg cells, an alternative 
possibility is that IL-10 gene induction does not require 
Foxp3 expression [29]. One of the important components 
in immune activation implicates the role of TH17 
subtype helper cells that secret IL-17 cytokine [30]. Co-
expression of T-bet and RORγt, which is found in 
subsets of IL-17-producing T-helper cells, may be an 
evolutionarily conserved transcriptional program that 
originally developed as part of the innate defense against 
infections but that also confers an increased risk of 
immune-mediated pathology [31]. The relationship 
between the various effector (Th1, Th17) and regulatory 
(Treg, Tr1) T cell subsets still needs to be clarified, in 
terms of antigen-specificity, development, and function. 
It seems that helminth-derive substance(s) may have 
impact on the innate immunity by targeting dendritic 
cells (DCs) and by regulating TLR signaling pathway. 
They may also down-regulate the Th1 response and 
polarize hosts’ response towards Th2 response (Fig.1). 
By balancing these responses, helminths product(s) can 
reduce inflammation in autoimmunity and in other 
inflammatory disorders.  
One approach would be to identify and isolate helminth-
derived molecules that will facilitate iTreg cell induction. 
Another possibility would be ex vivo expansion and 
reinfusion of Treg cells, a strategy being attempted for 
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the treatment of autoimmune diabetes [32, 33]. 
Specifically expanding Treg cells might facilitate Treg 
cell localization to the gut and enhance suppressive 
activity. Thus, understanding the mechanisms of immune 
homeostasis to the intestine may provide insight into the 
pathogenesis and treatment of inflammatory bowel 
disease, colitis, and diabetes type 1. This may also apply 
to inhibiting Multiple Sclerosis pathogenesis as it has 
previously been shown that suppression of IL-17 and 
enhancement of Treg response are involved in 
amelioration of EAE pathogenesis [14,15]. As regards to 
inhibiting allergy/asthma, it is likely that helminth-
derived molecules will inhibit mast cell activation 
induced by high affinity IgE receptor FcεRI, a critical 
receptor in patients with IgE-mediated allergy/asthma.  
4. CONCLUSION AND FUTURE DIRECTION 
Helminthic worms have evolved strategies to manipulate 
the host immune system, some of which may lead to a 
reduction in inflammation. Characterization of the ways 
in which these organisms mediate an anti-inflammatory 
response and identification of parasite-derived molecules 
involved in immune modulation will contribute to the 
discovery of novel therapeutic approaches for the 
treatment of inflammatory disease.  
Although helminth infections are implicated in protecting 
the host against immune-mediated diseases, they are also 
believed to cause significant morbidity and in some cases 
mortality in endemic areas through their effects on 
nutrition, growth and cognition; and they have 
deleterious effects on vaccine immune responses. Thus, 
it might be more practical to focus on individual 
helminth-derived immunomodulatory molecules to 
selectively induce regulatory immune responses 
(particularly those expressed during the chronic phase of 
infection) and avoid any possible side effects of natural 
worm infections. The introduction of live helminths in 
intestine may favor the outgrowth or suppression of 
certain bacteria in the gut, which in turn can impact 
host’s immunity. Hence, the priority would be to focus 
on the molecules released by helminth parasites (as 
excretory-secretory products). Clearly, further progress 
needs to be made in identifying parasite derived 
molecules, the ways in which they interact with the 
immune system and how they mediate 
immunomodulation in the genetically heterogeneous 
human population.  
Much remains to be resolved regarding identification of 
potential helminth-derived biomodulators, timing and 
dose of exposure to the agents as well as characterization 
of the modes of action so that synthetic analogues that 
mimic the effects can be generated. Analyses have 
consistently revealed bioactive molecules in extracts of 
helminths or in their excretory/secretory products that 
modulate the immune response of the host. It is our view 
that parasitic helminths are an untapped source of 
immunomodulatory substances that, in pure form, could 
become new drugs (or models for drug design) to treat 
disease. There are many examples of the partial 
characterization of helminth-derived immunomodulatory 
molecules, but these have not yet translated into new 
drugs, reflecting the difficulty of isolating and fully 
characterizing proteins, glycoproteins and lipid-based 
molecules from small amounts of parasite material. 
However, this should not deter the investigator, since 
analytical techniques are now being used to accrue 
considerable structural information on parasite-derived 
molecules, even when only minute quantities of tissue 
are available. With the introduction of methodologies to 
purify and structurally-characterize molecules from small 
amounts of tissue and the application of high throughput 
immunological assays, one would predict that an 
assessment of parasitic helminths will yield a variety of 
novel drug candidates in the coming years. 
In order to develop non-living parasite-derived 
therapeutic agents, the molecular motifs that are 
responsible for protection from immunopathology must 
first be identified, their cellular targets need to be 
characterized and gene families implicated in 
immunomodulation have to be defined. A few molecules 
have already been identified as potential candidates for 
immunotherapy. It is important that efforts continue to 
bring these molecules to the clinical setting as they hold 
potential for human therapy of immunopathological 
conditions. 
 
APPENDICES 
 
Figure 1 -  Helminth-derived product(s) are potential 
candidates for immunotherapy. These molecules mediate 
suppression through CD4+ regulatory T cells (Tregs, either 
Foxp3+ or Foxp3−), modulatory dendritic cells (DCs), and by 
impacting TLR signaling. Regulatory responses induced by 
helminth-derived substances include suppression of Th17, Th1 
response and polarization to Th2 response. Engagement of TLR 
on DCs may determine the Th2 polarization of the T cells. 
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